# Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Study · id `cardio:ct-nct01286012` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01286012](<https://clinicaltrials.gov/study/NCT01286012>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01286012

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

## Technical summary

Registry record NCT01286012. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-03-26.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 108 participants (enrolled count; ClinicalTrials.gov record NCT01286012, source copy `cardio:ctgov-nct01286012-2018-10-01`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01286012, source copy `cardio:ctgov-nct01286012-2018-10-01`, retrieved 2026-10-26)
- Primary completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01286012, source copy `cardio:ctgov-nct01286012-2018-10-01`, retrieved 2026-10-26)
- Completion: 2013-01 (actual) (ClinicalTrials.gov record NCT01286012, source copy `cardio:ctgov-nct01286012-2018-10-01`, retrieved 2026-10-26)
- Results first posted: 2014-03-26 (ClinicalTrials.gov record NCT01286012, source copy `cardio:ctgov-nct01286012-2018-10-01`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT01286012, source copy `cardio:ctgov-nct01286012-2018-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01286012-2018-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
- Acronym: PRIME
- Condition: End Stage Renal Disease
- Intervention (Drug): Soluble Ferric Pyrophosphate in liquid bicarbonate
- Intervention (Drug): Placebo: Conventional liquid bicarbonate
- Intervention (Drug): Erythrocyte Stimulating Agent (ESA)
- Intervention (Drug): Intravenous (IV) Iron
- Lead sponsor: Rockwell Medical Technologies, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Rockwell Medical Technologies, Inc. (`cardio:org-rockwell-medical-technologies-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients (`cardio:pubmed-26154926`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 76bc461b3e37b408a1373fabd0f1091c68e620e63be0ec0215988cc7f1e8ffd5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
